Background: Tyrosinase plays a key role in the formation of skin melanin. The excessive accumulation of skin melanin will cause the serious aesthetic problems for human beings. Hypothesis/purpose: To find the potent tyrosinase inhibitors using computational simulation from TCM Database@Taiwan. Study design: Inhibitors of tyrosinase have been thought as potential drugs for the decrease of melanin synthesis in the process of pigmentation. To develop new tyrosinase inhibitors, we performed a virtual screening from Traditional Chinese medicine (TCM) and Druglike Databases using the best 3D QSAR pharmacophore model as a 3D search query. Methods: A total of 109 compounds were obtained after filtering by Lipinski's rule of five. Finally, 148 compounds (22 from training set, 17 from test set, 109 from TCM and Druglike databases) were selected for further docking studies. De Novo Evolution designed the top 10 candidates from the docking results. Results: Hypo1 was selected as the best quantitative pharmacophore model, because Hypo1 has characters of the highest cost difference (353.773), the lowest RMS (1.985), the lowest Error (121.440), and the best correlation coefficient (0.933). By the analysis of interaction amino acids in the top 10 hits including two controls, HIS42, HIS60, HIS204, HIS208, ARG209 and VAL218 are identified as the key binding site residues, ARG209 and VAL218 are the critical residues for the inhibitory activity of tyrosinase. This finding is consistent with the results from literatures. Conclusion: De Novo Evolution study suggested Tyrosinase_1(star)_Evo_4, Tyrosinase_23(star)_Evo_7, magnolone.cdx_15_Evo_4, compound_2.cdx_2_Evo_2, Compound_B_Evo_5, Compound_C_Evo_9, Compound_D_Evo_6 and malabaricone_C.cdx_3_Evo_10 as the potential tyrosinase inhibitor candidates. De Novo Evolution study also suggested compound_2.cdx_2_Evo_2 as the most potential tyrosinase inhibitor candidate. A total of ten novel leading compounds were identified to have the favorable interaction with tyrosinase by the docking analyses.